Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Fallopian Tube Neoplasms 2Sarcoma 1Renal Insufficiency 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Congenital Abnormalities 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Cytarabine 22Mitoxantrone 7Etoposide 7Idarubicin 6tipifarnib 4Filgrastim 4Topotecan 3Sorafenib 3Lenalidomide 3Daunorubicin 3Cyclophosphamide 3Clofarabine 3Bortezomib 3Azacitidine 3veliparib 2tanespimycin 2fludarabine phosphate 2alvocidib 2Imatinib Mesylate 2Everolimus 2Carboplatin 2Arsenic Trioxide 2trebananib 1romidepsin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1ispinesib 1entinostat 1eltrombopag 1choline magnesium trisalicylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Acute × trebananib × Clear all
NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
24 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡